FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111330789> ?p ?o ?g. }

• W2111330789 endingPage "160" @default.
• W2111330789 startingPage "153" @default.
• W2111330789 abstract "Immunotherapy with dendritic cells (DC) may constitute a new and advantageous option for patients with chronic myeloid leukemia (CML) who respond to therapy with tyrosine kinase inhibitors (TKI), but do not reach complete cytogenetic or molecular remission. In this study, we evaluated the immunophenotype of DC generated from monocytes (Mo-DC) of patients with CML and the influence of TKI therapy on the results of CML-DC generation. We also measured the percentages of T regulatory cells (Tregs) as well as Th17 cells in 19 untreated patients suffering from CML, and in 28 CML patients treated with TKI. We found that DC can be reliably generated from the peripheral blood CD14+ cells of untreated CML patients. But we observed a persistent expression of CD14 monocyte marker on DC from CML patients, together with lower percentages of Mo-DC with expression of CD1a (p = 0.002), CD80 (p = 0.0005), CD83 (p = 0.0004), and CD209 (p = 0.02) compared to healthy donors. There was an adverse correlation between WBC count and the percentage of Mo-DC with co-expression of CD80 and CD86 (R = &#8211;0.63; p = 0.03). In patients treated with TKI, we observed higher efficacy of DC generation in seven-day cultures, compared to untreated patients. Expression of CD209 on DC was higher in patients treated with TKI (0.02). The duration of TKI therapy correlated adversely with MFI for CD1a (R = &#8211;0.49; p = 0.006) and positively with MFI for CD83 (R = 0.63; p = 0.01). Percentages of CD4+CD25highFoxP3+ cells (p = 0.0002) and Th17 cells (p = 0.02) were significantly higher in untreated CML patients compared to healthy controls. There was a significant correlation between the percentage of Treg cells and the percentage of peripheral blood basophiles (R = 0.821; p = 0.02). There were no changes in Tregs or Th17 cell percentages in CML patients after six months of TKI therapy. However, the expression of intracellular IL-17 in Th17 cells correlated negatively with the time of TKI therapy in the whole group of treated patients (R = &#8211;0.516; p = 0.04). We noted a correlation between IL-6 serum level and peripheral blood WBC count (R = 0.492; p = 0.04). There was also an inverse correlation between the serum level of IL-6 and the duration of TKI therapy (R = &#8211;0.66; p = 0.03). Taken together, our data shows that mature DC can be generated from CML patients treated with TKI, and that the yield of Mo-DC is higher in patients treated with TKI than in patients with active disease. This should encourage further trials with DC immunotherapy in patients with cytogenetic response after TKI therapy. We also found increased frequencies of T regulatory and Th17 cells in CML patients, which might suggest their potential role in immunity against this disease. Further studies are needed to determine if manipulation of these cell populations might improve the results of DC immunotherapy. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 153&#8211;160)" @default.
• W2111330789 created "2016-06-24" @default.
• W2111330789 creator A5007644421 @default.
• W2111330789 creator A5008820061 @default.
• W2111330789 creator A5016199509 @default.
• W2111330789 creator A5054065943 @default.
• W2111330789 creator A5057017325 @default.
• W2111330789 creator A5066945441 @default.
• W2111330789 creator A5084274389 @default.
• W2111330789 creator A5085299270 @default.
• W2111330789 creator A5087610667 @default.
• W2111330789 date "2011-04-19" @default.
• W2111330789 modified "2023-10-06" @default.
• W2111330789 title "Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors" @default.
• W2111330789 cites W151799953 @default.
• W2111330789 cites W1661544713 @default.
• W2111330789 cites W1966480069 @default.
• W2111330789 cites W1967333919 @default.
• W2111330789 cites W1969137358 @default.
• W2111330789 cites W1969381065 @default.
• W2111330789 cites W1977039692 @default.
• W2111330789 cites W1989496834 @default.
• W2111330789 cites W1990185718 @default.
• W2111330789 cites W2002185737 @default.
• W2111330789 cites W2002529947 @default.
• W2111330789 cites W2004678195 @default.
• W2111330789 cites W2004944010 @default.
• W2111330789 cites W2009954157 @default.
• W2111330789 cites W2013233132 @default.
• W2111330789 cites W2016656445 @default.
• W2111330789 cites W2017141756 @default.
• W2111330789 cites W2044298213 @default.
• W2111330789 cites W2049094526 @default.
• W2111330789 cites W2049372707 @default.
• W2111330789 cites W2052147215 @default.
• W2111330789 cites W2055234588 @default.
• W2111330789 cites W2063404733 @default.
• W2111330789 cites W2072090957 @default.
• W2111330789 cites W2075706560 @default.
• W2111330789 cites W2085321949 @default.
• W2111330789 cites W2093953981 @default.
• W2111330789 cites W2100325298 @default.
• W2111330789 cites W2104998827 @default.
• W2111330789 cites W2107235439 @default.
• W2111330789 cites W2112553705 @default.
• W2111330789 cites W2127078966 @default.
• W2111330789 cites W2133350434 @default.
• W2111330789 cites W2134819094 @default.
• W2111330789 cites W2138163780 @default.
• W2111330789 cites W2139276258 @default.
• W2111330789 cites W2142699991 @default.
• W2111330789 cites W2150475285 @default.
• W2111330789 cites W2150678612 @default.
• W2111330789 cites W2151055438 @default.
• W2111330789 cites W2152678202 @default.
• W2111330789 cites W84406250 @default.
• W2111330789 cites W2138002048 @default.
• W2111330789 cites W2146492595 @default.
• W2111330789 doi "https://doi.org/10.5603/fhc.2011.0022" @default.
• W2111330789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21526503" @default.
• W2111330789 hasPublicationYear "2011" @default.
• W2111330789 type Work @default.
• W2111330789 sameAs 2111330789 @default.
• W2111330789 citedByCount "10" @default.
• W2111330789 countsByYear W21113307892012 @default.
• W2111330789 countsByYear W21113307892013 @default.
• W2111330789 countsByYear W21113307892014 @default.
• W2111330789 countsByYear W21113307892015 @default.
• W2111330789 countsByYear W21113307892016 @default.
• W2111330789 countsByYear W21113307892017 @default.
• W2111330789 countsByYear W21113307892021 @default.
• W2111330789 crossrefType "journal-article" @default.
• W2111330789 hasAuthorship W2111330789A5007644421 @default.
• W2111330789 hasAuthorship W2111330789A5008820061 @default.
• W2111330789 hasAuthorship W2111330789A5016199509 @default.
• W2111330789 hasAuthorship W2111330789A5054065943 @default.
• W2111330789 hasAuthorship W2111330789A5057017325 @default.
• W2111330789 hasAuthorship W2111330789A5066945441 @default.
• W2111330789 hasAuthorship W2111330789A5084274389 @default.
• W2111330789 hasAuthorship W2111330789A5085299270 @default.
• W2111330789 hasAuthorship W2111330789A5087610667 @default.
• W2111330789 hasBestOaLocation W21113307891 @default.
• W2111330789 hasConcept C10205521 @default.
• W2111330789 hasConcept C121608353 @default.
• W2111330789 hasConcept C126322002 @default.
• W2111330789 hasConcept C154317977 @default.
• W2111330789 hasConcept C170493617 @default.
• W2111330789 hasConcept C176290653 @default.
• W2111330789 hasConcept C196166836 @default.
• W2111330789 hasConcept C202751555 @default.
• W2111330789 hasConcept C203014093 @default.
• W2111330789 hasConcept C2776090121 @default.
• W2111330789 hasConcept C2776960273 @default.
• W2111330789 hasConcept C2777583451 @default.
• W2111330789 hasConcept C2777701055 @default.
• W2111330789 hasConcept C2778170410 @default.
• W2111330789 hasConcept C2778297628 @default.
• W2111330789 hasConcept C2778461978 @default.

• next